|
1
|
Murad AM, Santiago FF, Petroianu A, Rocha
PR, Rodrigues MA and Rausch M: Modified therapy with
5-fluorouracil, doxorubicin, and methotrexate in advanced gastric
cancer. Cancer. 72:37–41. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Glimelius B, Hoffman K, Haglund U, Nyren O
and Sjoden PO: Initial or delayed chemotherapy with best supportive
care in advanced gastric cancer. Ann Oncol. 5:189–190.
1994.PubMed/NCBI
|
|
3
|
Shirasaka T, Shimamato Y, Ohshima H,
Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a
novel form of an oral 5-fluorouracil derivative (S-1) directed to
the potentiation of the tumor selective cytotoxicity of
5-fluorouracil by two biochemical modulators. Anticancer Drugs.
7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sakata Y, Ohtsu A, Horikoshi N, Sugimachi
K, Mitachi Y and Taguchi T: Late phase II study of novel oral
fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1
M otastat potassium) in advanced gastric cancer patients. Eur J
Cancer. 34:1715–1720. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Koizumi W, Kurihara M, Nakano S and
Hasegawa K: Phase II study of S-1, a novel oral derivative of
5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative
Gastric Cancer Study Group. Oncology. 58:191–197. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Koizumi W, Narahara H, Hara T, Takagane A,
Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama
W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H and
Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS trial): a phase III
trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Koo DH, Ryu MH, Ryoo BY, Lee SS, Moon JH,
Chang HM, Lee JL, Kim TW and Kang YK: Three-week combination
chemotherapy with S-1 and cisplatin as first-line treatment in
patients with advanced gastric cancer: a retrospective study with
159 patients. Gastric Cancer. 15:305–312. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Casaretto L, Sousa PLR and Mari JJ:
Chemotherapy versus support cancer treatment in advanced gastric
cancer: a meta-analysis. Braz J Med Biol Res. 39:431–440. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pirovano M, Maltoni M, Nanni O, Marinari
M, Indelli M, Zaninetta G, Petrella V, Bami S, Zecca E, Scarpi E,
Labianca R, Amadori D and Luporini G: A new palliative prognostic
score: A first step for the staging of terminally ill cancer
patients. J Pain Symptom Manage. 17:231–239. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tassinari D, Montanari L, Maltoni M,
Ballardini M, Piancastelli A, Musi M, Porzio G, Minotti V, Caraceni
A, Poggi B, Stella A, Aielli F and Scarpi E: The palliative
prognostic score and survival in patients with advanced solid
tumors receiving chemotherapy. Support Care Cancer. 16:359–370.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maltoni M, Nanni O, Pirovano M, Scarpi E,
Indelli M, Martini C, Monti M, Amoldi E, Piva L, Ravaioli A,
Cruciani G, Labianca R and Amadori D: Successful validation of the
palliative prognostic score in terminally ill cancer patients. J
Pain Symptom Manage. 17:240–247. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Japanese Gastric Cancer Association:
Japanese classification of gastric carcinoma. 3rd English edition.
Gastric Cancer. 14:101–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Geels P, Eisenhauer E, Bezjak A, Zee B and
Day A: Palliative effect of chemotherapy: objective tumor response
is associated with symptom improvement in patients with metastatic
breast cancer. J Clin Oncol. 18:2395–2405. 2000.PubMed/NCBI
|
|
14
|
Browner I and Carducci MA: Palliative
chemotherapy: historical perspective, applications and
controversies. Semin Oncol. 32:145–155. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Glare PA, Eychmueller S and McMahon P:
Diagnostic accuracy of the palliative prognostic score in
hospitalized patients with advanced cancer. J Clin Oncol.
22:4823–4828. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stone CA, Tiernan E and Dooley BA:
Prospective validation of the palliative prognostic index in
patients with cancer. J Pain Symptom Manage. 35:617–622. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stiel S, Bertram L, Neuhaus S, Nauck F,
Ostgathe C, Elsner F and Radbruch L: Evaluation and comparison of
two prognostic scores and the physicians’ estimate of survival in
terminally ill patients. Support Care Cancer. 18:43–49. 2010.
|
|
18
|
Massacesi C, Marcucci F, Rocchi MB,
Mazzanti P, Pilone A and Bonsignori M: Factors predicting
docetaxel-related toxicity: experience at a single institution. J
Chemother. 16:86–93. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fujii M: Chemotherapy for advanced gastric
cancer: ongoing phase III study of S-1 alone versus S-1 and
docetaxel combination (JACCRO GC03 study). Int J Clin Oncol.
13:201–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
